<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000635900">
  <TermName>Stanford V regimen</TermName>
  <TermPronunciation>(STAN-furd … REH-jih-men)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>An abbreviation for a chemotherapy combination that is used to treat Hodgkin lymphoma and is being studied in the treatment of other types of cancer. It includes the drugs mechlorethamine, doxorubicin hydrochloride, vinblastine sulfate, vincristine sulfate, bleomycin sulfate, etoposide phosphate, and prednisone and was developed at Stanford University. Also called Stanford V.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000723245" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Stanford V regimen&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000723246" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen Stanford V&quot;" language="es" id="_4"/>
  <SpanishTermName>régimen Stanford V</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Nombre de una quimioterapia combinada que se usa para el tratamiento del linfoma de Hodgkin y que está en estudio para el tratamiento de otros tipos de cáncer. Incluye los medicamentos clormetina, clorhidrato de doxorrubicina, sulfato de vinblastina, sulfato de vincristina, sulfato de bleomicina, fosfato de etopósido y prednisona. Se formuló en la Universidad de Stanford. También se llama Stanford V.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-02-23</DateFirstPublished>
  <DateLastModified>2010-05-05</DateLastModified>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000636200" url="/about-cancer/treatment/drugs/STANFORDV">STANFORD V</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
